Vedolizumab Versus Other Biologics and the Risk of Venous Thromboembolism in Patients with Pediatric-Onset Inflammatory Bowel Diseases: A Target Trial Emulation Study
Open Access
- 8 October 2025
- journal article
- Published by Springer Nature in Pediatric Drugs
- Vol. 27 (6) , 761-770
Abstract
Pediatric-onset inflammatory bowel diseases (IBD) are associated with an elevated risk of venous thromboembolism (VTE). However, data on the VTE risk in these patients treated with novel biologics, particularly vedolizumab, remain limited. To evaluate the association between vedolizumab and the risk of VTE compared with other biologics in patients with pediatric-onset Crohn's disease (CD) or ulcerative colitis (UC). We emulated a target trial using electronic health records from the TriNetX research network. The study included patients with CD or UC diagnosed before the age of 18 years who were treated with vedolizumab, ustekinumab, or anti-tumor necrosis factor (TNF) agents. Comparative groups were generated using 1:1 propensity-score matching based on relevant confounders. The primary outcome was the occurrence of any VTE within 12 months of follow-up. Cox proportional hazards models were used to compare the risk of VTE between vedolizumab-treated patients and those treated with anti-TNF agents and ustekinumab. A total of 1806 matched patient pairs were analyzed across four comparisons: patients treated with vedolizumab versus anti-TNF agents (CD = 407 pairs; UC = 443 pairs), and vedolizumab versus ustekinumab (CD = 563 pairs; UC = 393 pairs), respectively. Patients with CD receiving vedolizumab had a significantly higher risk of VTE compared with those receiving anti-TNF therapy (hazard ratio [HR] 8.63; 95% confidence interval [CI] 1.08-69.10; p = 0.014). A higher VTE risk was also observed in vedolizumab-treated patients with CD compared with those treated with ustekinumab (HR 4.64; 95% CI 1.35-15.97; p = 0.007). In contrast, no significant difference in VTE risk was found between vedolizumab and either comparator group in patients with UC. Treatment with vedolizumab was associated with a higher incidence of VTE than anti-TNF agents or ustekinumab among individuals with CD. Prospective cohort studies are warranted to validate the safety of biologic therapy for pediatric patients with CD.Keywords
This publication has 40 references indexed in Scilit:
- The inflammatory effects of TNF-α and complement component 3 on coagulationScientific Reports, 2018
- Steroid but not Biological Therapy Elevates the risk of Venous Thromboembolic Events in Inflammatory Bowel Disease: A Meta-AnalysisJournal of Crohn's and Colitis, 2017
- Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel DiseaseInflammatory Bowel Diseases, 2016
- Antitumor Necrosis Factor-α Therapy Is Associated With Reduced Risk of Thromboembolic Events in Hospitalized Patients With Inflammatory Bowel DiseaseJournal of Clinical Gastroenterology, 2016
- Combined oral contraceptives, thrombophilia and the risk of venous thromboembolism: a systematic review and meta‐analysisJournal of Thrombosis and Haemostasis, 2016
- Cross Talk Pathways Between Coagulation and InflammationCirculation Research, 2016
- Increased Risk of Venous Thromboembolic Events With Corticosteroid vs Biologic Therapy for Inflammatory Bowel DiseaseClinical Gastroenterology and Hepatology, 2015
- Inflammatory Bowel Disease Is Associated With an Increased Incidence of Cardiovascular EventsAmerican Journal of Gastroenterology, 2011
- Incidence and Prevalence of Inflammatory Bowel Disease in a Northern California Managed Care Organization, 1996-2002American Journal of Gastroenterology, 2008
- Antithrombotic activity of TNF-αJournal of Clinical Investigation, 2003